Response to "UNCERTAINTY MANAGEMENT IN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT DECISION-MAKING ON DRUGS: GUIDANCE OF THE HTAi-DIA WORKING GROUP".
作者信息
Grimm Sabine Elisabeth, Pouwels Xavier G L V, Ramaekers Bram L T, Wijnen Ben, Grutters Janneke, Joore Manuela A
机构信息
Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre and Maastricht Health Economics and Technology Assessment Centre, School for Public Health and Primary Care (CAPHRI), Maastricht, The Netherlands.
Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands.
出版信息
Int J Technol Assess Health Care. 2023 Oct 12;39(1):e70. doi: 10.1017/S026646232300260X.
Abstract
摘要
相似文献
1
Response to "UNCERTAINTY MANAGEMENT IN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT DECISION-MAKING ON DRUGS: GUIDANCE OF THE HTAi-DIA WORKING GROUP".
Int J Technol Assess Health Care. 2023 Oct 12;39(1):e70. doi: 10.1017/S026646232300260X.
2
Response to uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group - author's reply.
Int J Technol Assess Health Care. 2023 Dec 18;40(1):e1. doi: 10.1017/S0266462323002817.
3
Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group.
Int J Technol Assess Health Care. 2023 Jun 16;39(1):e40. doi: 10.1017/S0266462323000375.
4
Lifecycle HTA: promising applications and a framework for implementation. An HTAi Global Policy Forum Task Force report.
Int J Technol Assess Health Care. 2024 May 10;40(1):e50. doi: 10.1017/S0266462324000187.
5
The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.
Pharmacoeconomics. 2017 Dec;35(12):1287-1296. doi: 10.1007/s40273-017-0562-9.
6
TOWARD A SHIFTING HEALTH TECHNOLOGY ASSESSMENT PARADIGM: REACTIONS TO POLICY FORUM DISCUSSIONS.
Int J Technol Assess Health Care. 2015 Jan;31(4):228-9. doi: 10.1017/S0266462315000483.
7
Managed Entry Agreements: Policy Analysis From the European Perspective.
Value Health. 2020 Apr;23(4):425-433. doi: 10.1016/j.jval.2019.12.008.
8
Burning Issues in Health Technology Assessment and Policy Making: What's Keeping Senior Health Technology Assessment Users and Producers up at Night?
Int J Technol Assess Health Care. 2020;36(1):5-7. doi: 10.1017/S0266462319003477.
9
HTAi Policy Forum: keeping HTA on track.
Int J Technol Assess Health Care. 2014 Jul;30(3):251-2. doi: 10.1017/S0266462314000336. Epub 2014 Jul 31.
10
Dangerous omissions: the consequences of ignoring decision uncertainty.
Health Econ. 2011 Feb;20(2):212-24. doi: 10.1002/hec.1586.
引用本文的文献
1
Response to uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group - author's reply.
Int J Technol Assess Health Care. 2023 Dec 18;40(1):e1. doi: 10.1017/S0266462323002817.
本文引用的文献
1
Response to uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group - author's reply.
Int J Technol Assess Health Care. 2023 Dec 18;40(1):e1. doi: 10.1017/S0266462323002817.
2
Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations.
Pharmacoeconomics. 2023 Jun;41(6):619-632. doi: 10.1007/s40273-023-01242-1. Epub 2023 Mar 21.
3
Dealing With Uncertainty in Early Health Technology Assessment: An Exploration of Methods for Decision Making Under Deep Uncertainty.
Value Health. 2023 May;26(5):694-703. doi: 10.1016/j.jval.2022.08.012. Epub 2022 Oct 15.
4
Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma.
BMC Med Res Methodol. 2022 Oct 15;22(1):272. doi: 10.1186/s12874-022-01745-z.
5
Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison.
Med Decis Making. 2022 Oct;42(7):956-968. doi: 10.1177/0272989X221100112. Epub 2022 May 19.
6
State of the ART? Two New Tools for Risk Communication in Health Technology Assessments.
Pharmacoeconomics. 2021 Oct;39(10):1185-1196. doi: 10.1007/s40273-021-01060-3. Epub 2021 Jul 19.
7
Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study.
Value Health. 2021 Jul;24(7):983-994. doi: 10.1016/j.jval.2021.01.004. Epub 2021 Mar 31.
8
Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study.
Health Technol Assess. 2021 Jun;25(37):1-124. doi: 10.3310/hta25370.
9
The communication of uncertainty in health: A scoping review.
Patient Educ Couns. 2021 Aug;104(8):1945-1961. doi: 10.1016/j.pec.2021.01.034. Epub 2021 Feb 1.
10
Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland.
Health Policy. 2021 Mar;125(3):307-319. doi: 10.1016/j.healthpol.2020.12.007. Epub 2020 Dec 24.
Zotero 插件